David Luke Fischer, M.D., Ph.D.
Affiliations: | 2006-2010 | Radiology, Neurology | Michigan State University, East Lansing, MI |
| 2010-2018 | Translational Science and Molecular Medicine | Michigan State University, East Lansing, MI | |
| 2018-2022 | Neurology | University of Alabama, Birmingham, Birmingham, AL, United States | |
| 2022- | Neurology | University of California, San Francisco, San Francisco, CA |
Area:
Alpha-Synuclein, Parkinson's disease, deep brain stimulation, brain-derived neurotrophic factorGoogle:
"D. Luke Fischer"Bio:
Mean distance: 18.69 (cluster 19) | S | N | B | C | P |
Parents
Sign in to add mentor| Kevin L. Berger | research assistant | 2007-2010 | Michigan State | |
| Andrea Cathryn Bozoki | research assistant | 2007-2010 | Michigan State | |
| Caryl E. Sortwell | grad student | 2010-2015 | Michigan State | |
| (Dissertation: "The Neuroprotective Potential of STN DBS and the Role of BDNF") | ||||
| Lea Tenenholz Grinberg | post-doc | 2024- | UCSF | |
| (Neuropathology Research Fellowship Mentor) | ||||
| William W. Seeley | post-doc | 2024- | UCSF | |
| (Neuropathology Research Fellowship Co-Mentor) | ||||
| Caryl E. Sortwell | post-doc | 2015-2016 | Michigan State | |
| David G. Standaert | post-doc | 2020-2022 | UAB | |
| (Co-Mentor with Dr. Volpicelli-Daley) | ||||
| Laura A. Volpicelli-Daley | post-doc | 2020-2022 | UAB | |
| Bruce L. Miller | post-doc | 2022-2024 | UCSF | |
| (Behavioral Neurology Clinical Fellowship Co-Director) | ||||
| Howard Rosen | post-doc | 2022-2024 | UCSF | |
| (Behavioral Neurology Clinical Fellowship Director) | ||||
Collaborators
Sign in to add collaborator| Lawren Vandevrede | collaborator | 2023- | UCSF |
| Timothy J. Collier | collaborator | 2010-2018 | Michigan State |
| Jack W. Lipton | collaborator | 2011-2018 | Michigan State |
| Fredric P. Manfredsson | collaborator | 2012-2018 | Michigan State |
| Erik Roberson | collaborator | 2020-2022 | UAB |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ellens NR, Fischer DL, Meldau JE, et al. (2020) External Ventricular Drain Placement Accuracy and Safety When Done by Midlevel Practitioners. Neurosurgery. 84: 235-241 |
| Fischer DL, Sortwell CE. (2018) BDNF provides many routes toward STN DBS-mediated disease modification. Movement Disorders : Official Journal of the Movement Disorder Society |
| Duffy MF, Collier TJ, Patterson JR, et al. (2018) Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation. 15: 169 |
| Fischer DL, Auinger P, Goudreau JL, et al. (2018) Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease. Parkinsonism & Related Disorders |
| Fischer DL, Manfredsson FP, Kemp CJ, et al. (2017) Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression. Scientific Reports. 7: 16356 |
| Fischer DL, Manfredsson FP, Sortwell CE. (2017) Can STN DBS protect both nigral somata and innervation of the striatum? Annals of Neurology |
| Fischer DL, Kemp CJ, Cole-Strauss A, et al. (2017) Subthalamic Nucleus Deep Brain Stimulation Employs TrkB Signaling for Neuroprotection and Functional Restoration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience |
| Su X, Fischer DL, Li X, et al. (2017) Alpha-Synuclein mRNA Is Not Increased. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Polinski NK, Manfredsson FP, Benskey MJ, et al. (2016) Impact of age and vector construct on striatal and nigral transgene expression. Molecular Therapy. Methods & Clinical Development. 3: 16082 |
| Fischer DL, Gombash SE, Kemp CJ, et al. (2016) Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease. Methods in Molecular Biology (Clifton, N.J.). 1382: 367-82 |